MarketBeat cites USD 8.50 consensus target for Alvotech stock

Published on 10/15/2026 at 20:39 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Q2 revenue reached USD 106.00 million, above USD 103.00 million consensus. Alvotech stock costs EUR 4.80 on October 15, 2026, up 4.26 percent on Nasdaq.

Analyst view and reporting date

Eight brokerages support a USD 8.50 average 12-month target in the October 13, 2026 MarketBeat report.
Second-quarter revenue reached USD 106.00 million against USD 103.00 million consensus on August 20, 2026.
Alvotech stock costs EUR 4.80 at Lang & Schwarz on October 15, 2026 at 8:33 p.m. CEST, up 4.26 percent on Nasdaq.
Alvotech is scheduled to report third-quarter 2026 results on November 11, 2026.

Alvotech, LU2458332611, Illustration mit AI erstellt.

MarketBeat cited an average 12-month price target of USD 8.50 for Alvotech on October 13, 2026, based on eight brokerages. That target is 57.70 percent above the Nasdaq price of USD 5.39 at 2:38 p.m. EDT on October 15, 2026. At Lang & Schwarz, Alvotech stock was trading at EUR 4.80 on October 15, 2026 at 8:33 p.m. CEST.

Revenue beat expectations in the second quarter

Alvotech reported second-quarter revenue of USD 106.00 million on August 20, 2026, compared with a USD 103.00 million consensus estimate, according to MarketBeat. Adjusted loss per share was USD 0.11, wider than the USD 0.05 consensus loss. The comparison keeps the operating picture mixed: revenue exceeded expectations, while the adjusted loss was larger than forecast.

Price sits below the yearly high

The Nasdaq quote was USD 5.39 at 2:38 p.m. EDT on October 15, 2026, up 4.26 percent from the USD 5.17 prior close. Trading volume stood at 620,784 shares against an average of 1,071,762 shares. The intraday range was not used as a separate market measure because the same dated quote supplied no high or low.

Alvotech's 52-week range was USD 2.94 to USD 9.00, placing the Nasdaq price 40.33 percent below the high and 83.33 percent above the low. The stock's one-year performance was minus 36.71 percent, according to Simply Wall St.

Valuation and the next reporting date

Alvotech had a market capitalization of USD 1.9 billion and a trailing P/E ratio of minus 8.50 on October 15, 2026. No dividend yield was reported in the quote. The company website lists its second-quarter 2026 financial release dated August 19, 2026, while Simply Wall St lists November 11, 2026 as the next reporting date. That calendar point gives the valuation discussion a concrete near-term reference.

Alvotech develops and manufactures biosimilar medicines. Its investor-relations page describes a vertically integrated model covering cell-line development through fill and finish manufacturing, with commercial partners handling market access in several regions. The company had 1,279 full-time employees in the latest company profile.

Comparison with peers

Alvotech: up 4.26 percent, P/E minus 8.50, market capitalization USD 1.9 billion
Rani Therapeutics Holdings (Nasdaq, USD): up 1.97 percent, P/E minus 2.54, market capitalization USD 44.6 million
Catalent (NYSE, USD): unchanged, P/E minus 11.02, market capitalization USD 11.5 billion

Stock position in context

The current picture combines a sharp session gain with a stock still well below its 52-week high and a negative trailing P/E. The USD 8.50 consensus target is a valuation reference, not a forecast adopted by this report. The next earnings release should provide the next dated test of revenue delivery and loss reduction.

Alvotech stock was trading at EUR 4.80 at Lang & Schwarz on October 15, 2026 at 8:33 p.m. CEST, up 4.26 percent on Nasdaq versus the USD 5.17 close of October 14, 2026. The further course of trading is shown by the continuously updated real-time quote of Alvotech stock.